470 results on '"Doyen C"'
Search Results
2. La remédiation cognitive pour l’inclusion des enfants et des adolescents avec troubles du neurodéveloppement et/ou émotionnels
3. Modulation Of HCI in I/O analog devices Through Process Specifications
4. Daratumumab: Therapeutic asset, biological trap!
5. Insight Into HCI Reliability on I/O Nitrided Devices
6. Thérapie par remédiation cognitive chez les enfants : données de la littérature et application clinique dans un service de psychiatrie de l’enfant et de l’adolescent
7. Diversité des prises en charge hospitalières de l’anorexie mentale en psychiatrie en France
8. Trastornos de la conducta alimentaria en niños y adolescentes
9. Criminaliter agere in tema di falso nel peso e nella misura
10. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors
11. CMOS Pixel Potentials Extraction Method From Test Structures Based on EKV Model
12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
13. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
14. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
15. Melatonin in children with autistic spectrum disorders: recent and practical data
16. Family therapy in the treatment of adolescent anorexia nervosa: Current research evidence and its therapeutic implications
17. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
18. Anorexie mentale du sujet prépubère
19. Troubles du comportement alimentaire prépubertaires
20. Phases du développement du comportement alimentaire
21. Traitement médicamenteux
22. Surveillance de la grossesse au troisième trimestre
23. Surveillance de la grossesse au deuxième trimestre
24. Liste des collaborateurs
25. Les stratégies d'attachement, leur transmission et le fonctionnement familial d'adolescentes anorexiques mentales
26. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma
27. THE FREQUENCY OF CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PLATELET TRANSFUSION DEPENDENT PATIENTS BEFORE AND AFTER INTRODUCTION OF PATHOGEN INACTIVATED COMPONENTS: A 9 YEAR HEMOVIGILANCE SURVEY: 4C-S27–04
28. Abnormal psychosocial situations among inpatients from a child and adolescent psychiatric department in a teaching hospital in France
29. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial
30. Influence on HLA Alloimmunisation Frequency in Hematology Patients Supported with INTERCEPT Pathogen Inactivated (PI) Platelet Components (PC): SP208
31. Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: 0117
32. MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients
33. A Highly Reliable Back Side Illuminated Pixel against Plasma Induced Damage
34. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas
35. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia
36. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT: 221
37. The t(14;20)(q32;q12): A Rare Cytogenetic Change in Multiple Myeloma (MM) Associated with Poor Outcome: A182
38. Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT: A051
39. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT
40. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
41. Acute leukaemia in paroxysmal nocturnal haemoglobinuria. Case report and review of the literature
42. Impact of Pathogen Inactivation (INTERCEPT Blood System®) on Platelet Utilization During Three Years of Routine Use: S44–030I
43. IMPACT OF PHOTOCHEMICAL TREATMENT (INTERCEPT) ON PLATELET USE IN ROUTINE PRACTICE: P-378
44. Lymphomes folliculaires
45. High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age
46. Role of ATG in fludarabine phosphate-based nonmyeloablative stem cell transplantation: a national dose-finding study
47. Preliminary results of the IFM9903 and IFM9904 protocols comparing autologous followed by mini-allogeneic transplantation and double transplant in high-risk de novo multiple myeloma
48. Screening for Aspergillus galactomannan antigenemia in a haematology unit: how useful is it in daily practice?
49. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol
50. PRESENCE OF GLYCOSYLATED POLYPEPTIDES IN GLIADIN AND GLUTENIN FRACTIONS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.